Skip to Main Content

Paper Details

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Ann Oncol
87
2022
Author NameAffiliation
David C SmithUniversity of Michigan Health System ann arbor
  • 1 - 1

Datasets

Release 1.2